Edwards Lifesciences (EW) has seen its stock trend lower over the past month, down about 6%. Investors are keeping an eye on recent performance and fundamentals as they review the company’s latest results and outlook.

See our latest analysis for Edwards Lifesciences.

Despite some recent weakness in the share price, with a 1-month share price return of -5.8%, Edwards Lifesciences still boasts a 1-year total shareholder return of 10.2%. While momentum has faded since the start of the year, its longer-term returns remind investors that performance can shift quickly in this sector.

If medtech’s shifts have you curious, the next logical step is to discover other leading healthcare stocks using our free list: See the full list for free.

The question now becomes whether Edwards Lifesciences is currently undervalued with room to run, or if the market has already factored in expectations for future growth and left little upside for new buyers.

Edwards Lifesciences' most widely followed narrative pegs fair value at $87.73, which is notably above its last close price of $75.19. This indicates that the share price may not fully reflect optimism about near-term product launches and market expansion.

The planned launch of the transcatheter tricuspid valve EVOQUE in 2024 is anticipated to uniquely position Edwards to gain market share and increase revenues as it becomes the first company to develop and offer this therapy.

Read the complete narrative.

Curious how this valuation stacks up? The narrative is based on future earnings and ambitious global expansion targets from groundbreaking heart therapies, along with some bold assumptions about profit margins and future multiples. Want a sneak peek at the surprising financial leaps and what’s driving this price target? Only the full narrative reveals what’s behind the bullish call.

Result: Fair Value of $87.73 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, increased tariffs and EPS dilution from the JenaValve acquisition could put pressure on margins and challenge the robust growth projections outlined above.

Find out about the key risks to this Edwards Lifesciences narrative.

If you would rather investigate the numbers first-hand or want to shape your own perspective, you can build a narrative for Edwards Lifesciences in just a few minutes, all on your terms. Do it your way

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Edwards Lifesciences.

Your next big win might be just a click away, so do not let today’s ideas limit your growth potential. Here are three top stock themes making waves right now:

Spot undervalued potential by checking out these 892 undervalued stocks based on cash flows , which have strong future cash flow prospects and could be primed for a market re-rating.

Target rich income streams by investigating these 18 dividend stocks with yields > 3% , offering yields above 3% and steady payout track records.

Pursue disruptive innovation through these 25 AI penny stocks , with companies making headlines for their breakthroughs and promising AI-driven business models.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include EW .

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Edwards Lifesciences (EW) has seen its stock trend lower over the past month, down about 6%. Investors are keeping an eye on recent performance and fundamentals as they review the company’s latest results and outlook.

See our latest analysis for Edwards Lifesciences.

Despite some recent weakness in the share price, with a 1-month share price return of -5.8%, Edwards Lifesciences still boasts a 1-year total shareholder return of 10.2%. While momentum has faded since the start of the year, its longer-term returns remind investors that performance can shift quickly in this sector.

If medtech’s shifts have you curious, the next logical step is to discover other leading healthcare stocks using our free list: See the full list for free.

The question now becomes whether Edwards Lifesciences is currently undervalued with room to run, or if the market has already factored in expectations for future growth and left little upside for new buyers.

Edwards Lifesciences' most widely followed narrative pegs fair value at $87.73, which is notably above its last close price of $75.19. This indicates that the share price may not fully reflect optimism about near-term product launches and market expansion.

The planned launch of the transcatheter tricuspid valve EVOQUE in 2024 is anticipated to uniquely position Edwards to gain market share and increase revenues as it becomes the first company to develop and offer this therapy.

Read the complete narrative.

Curious how this valuation stacks up? The narrative is based on future earnings and ambitious global expansion targets from groundbreaking heart therapies, along with some bold assumptions about profit margins and future multiples. Want a sneak peek at the surprising financial leaps and what’s driving this price target? Only the full narrative reveals what’s behind the bullish call.

Result: Fair Value of $87.73 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, increased tariffs and EPS dilution from the JenaValve acquisition could put pressure on margins and challenge the robust growth projections outlined above.

Find out about the key risks to this Edwards Lifesciences narrative.

If you would rather investigate the numbers first-hand or want to shape your own perspective, you can build a narrative for Edwards Lifesciences in just a few minutes, all on your terms. Do it your way

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Edwards Lifesciences.

Your next big win might be just a click away, so do not let today’s ideas limit your growth potential. Here are three top stock themes making waves right now:

Spot undervalued potential by checking out these 892 undervalued stocks based on cash flows , which have strong future cash flow prospects and could be primed for a market re-rating.

Target rich income streams by investigating these 18 dividend stocks with yields > 3% , offering yields above 3% and steady payout track records.

Pursue disruptive innovation through these 25 AI penny stocks , with companies making headlines for their breakthroughs and promising AI-driven business models.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include EW .

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Your next big win might be just a click away, so do not let today’s ideas limit your growth potential. Here are three top stock themes making waves right now:

Spot undervalued potential by checking out these 892 undervalued stocks based on cash flows , which have strong future cash flow prospects and could be primed for a market re-rating.

Target rich income streams by investigating these 18 dividend stocks with yields > 3% , offering yields above 3% and steady payout track records.

Pursue disruptive innovation through these 25 AI penny stocks , with companies making headlines for their breakthroughs and promising AI-driven business models.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include EW .

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com